Table 2 Description of the main adverse events
Toxicity N = 170 | G0 n (%) | G1 n (%) | G2 n (%) | G3 n (%) | G4 n (%) | G5 n (%) | Severe toxicity (G3 + G4 + G5*) n (%) [%95%CI] |
|---|---|---|---|---|---|---|---|
Overall adverse events | 26 (15.3) | 35 (20.6) | 58 (34.1) | 38 (22.4) | 12 (7.1) | 1 (0.6) | 65 (38.2) [30.9—46.0] |
Neurotoxicity | 114 (67.1) | 31 (18.2) | 20 (11.8) | 5 (2.9) | 0 (0.0) | 0 (0.0) | 25 (14.7)*[9.75—20.9] |
Neutropenia | 118 (69.4) | 15 (8.8) | 11 (6.5) | 16 (9.4) | 10 (5.9) | 0 (0.0) | 26 (15.3) [10.2—21.6] |
Constipation | 145 (85.3) | 16 (9.4) | 8 (4.7) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) [0.015—3.23] |
Alopecia | 132 (77.6) | 25 (14.7) | 13 (7.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Asthenia | 84 (49.4) | 38 (22.4) | 38 (22.4) | 10 (5.9) | 0 (0.0) | 0 (0.0) | 10 (5.9) [2.86—10.6] |
Nausea | 145 (85.3) | 19 (11.2) | 6 (3.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |